STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Phase 1 Withdrawn
Testing the Safety of CB-5339 in Patients With Cancer
Phase 1 Withdrawn
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
Phase 1 Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Phase 1 Withdrawn
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Phase 1 Withdrawn
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Phase 1 Withdrawn
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Phase 1 Withdrawn
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Phase 1 Withdrawn
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Phase 1 Withdrawn
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Phase 1 Withdrawn
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Phase 1 Withdrawn
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
Phase 1 Withdrawn
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase 1 Withdrawn
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
Phase 1 Withdrawn
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
Phase 1 Withdrawn
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
Phase 1 Withdrawn
Safety Study of 2DG With Stereotactic Radiosurgery
Phase 1 Withdrawn
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
Phase 1 Withdrawn
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Phase 1 Withdrawn